A proof‑of‑concept study showed brepocitinib, a dual JAK1/TYK2 inhibitor licensed by Priovant (a Roivant subsidiary) from Pfizer, met endpoints in cutaneous sarcoidosis, a rare inflammatory skin disease with no FDA‑approved treatments. The company said the result positions the asset for pivotal testing. The readout supports brepocitinib’s potential in rare immune‑mediated dermatologic indications; Roivant’s licensing strategy aims to accelerate development by pivoting licensed molecules into underserved rare‑disease markets. The study’s details—patient numbers, effect sizes, and safety signals—will be central to regulatory strategy and pivotal trial design. If regulators accept the planned pivotal program, brepocitinib could move toward registration and broaden Roivant’s pipeline of speciality immunology assets, creating commercial potential in orphan indications where unmet need and pricing dynamics differ from larger autoimmune markets.